A noncontrolled trial of anti-TNF-α chimeric monoclonal antibody (infliximab, Remicade(®)) in exudative age-related macular degeneration

P Martin van Hagen, G Seerp Baarsma, Christel E van Bilsen, Robert W Kuijpers, Jan A van Laar, Marianne van der Ent, Paul L van Daele, Nico J Veeger, Johannes R Vingerling, Tom O Missotten

Research output: Contribution to journalLetterResearchpeer-review

Original languageEnglish
Pages (from-to)e691-2
JournalActa Ophthalmologica
Volume92
Issue number8
DOIs
Publication statusPublished - Dec 2014

Keywords

  • Administration, Topical
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal/adverse effects
  • Antibodies, Monoclonal/adverse effects
  • Contrast Sensitivity/drug effects
  • Exudates and Transudates
  • Humans
  • Infliximab
  • Ophthalmic Solutions
  • Tumor Necrosis Factor-alpha
  • Visual Acuity/drug effects
  • Wet Macular Degeneration/drug therapy

Cite this